1. Home
  2. ARQT vs MSEX Comparison

ARQT vs MSEX Comparison

Compare ARQT & MSEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • MSEX
  • Stock Information
  • Founded
  • ARQT 2016
  • MSEX 1897
  • Country
  • ARQT United States
  • MSEX United States
  • Employees
  • ARQT N/A
  • MSEX N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • MSEX Water Supply
  • Sector
  • ARQT Health Care
  • MSEX Utilities
  • Exchange
  • ARQT Nasdaq
  • MSEX Nasdaq
  • Market Cap
  • ARQT 1.1B
  • MSEX 1.2B
  • IPO Year
  • ARQT 2020
  • MSEX N/A
  • Fundamental
  • Price
  • ARQT $10.19
  • MSEX $66.33
  • Analyst Decision
  • ARQT Strong Buy
  • MSEX Hold
  • Analyst Count
  • ARQT 5
  • MSEX 1
  • Target Price
  • ARQT $14.40
  • MSEX $61.00
  • AVG Volume (30 Days)
  • ARQT 2.3M
  • MSEX 88.9K
  • Earning Date
  • ARQT 11-06-2024
  • MSEX 10-31-2024
  • Dividend Yield
  • ARQT N/A
  • MSEX 2.08%
  • EPS Growth
  • ARQT N/A
  • MSEX 24.58
  • EPS
  • ARQT N/A
  • MSEX 2.30
  • Revenue
  • ARQT $138,708,000.00
  • MSEX $183,372,000.00
  • Revenue This Year
  • ARQT $208.32
  • MSEX $15.27
  • Revenue Next Year
  • ARQT $48.56
  • MSEX $6.33
  • P/E Ratio
  • ARQT N/A
  • MSEX $28.74
  • Revenue Growth
  • ARQT 182.84
  • MSEX 10.14
  • 52 Week Low
  • ARQT $1.76
  • MSEX $45.42
  • 52 Week High
  • ARQT $13.17
  • MSEX $73.47
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 57.11
  • MSEX 48.97
  • Support Level
  • ARQT $8.90
  • MSEX $64.49
  • Resistance Level
  • ARQT $10.42
  • MSEX $66.32
  • Average True Range (ATR)
  • ARQT 0.68
  • MSEX 1.89
  • MACD
  • ARQT 0.06
  • MSEX -0.22
  • Stochastic Oscillator
  • ARQT 61.90
  • MSEX 34.07

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About MSEX Middlesex Water Company

Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm primarily operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.

Share on Social Networks: